| Liver Disease Diagnosis and Treatment | Lifetime | 33 | FI 1 | 99.91 |
| Diet, Metabolism, and Disease | Lifetime | 15 | FI 1 | 99.85 |
| Diet and metabolism studies | Lifetime | 58 | FI 1 | 99.82 |
| Metabolism, Diabetes, and Cancer | Lifetime | 43 | FI 2 | 99.74 |
| Diabetes Management and Research | Lifetime | 51 | FI 2 | 99.71 |
| Diabetes Treatment and Management | Lifetime | 66 | FI 2 | 99.67 |
| Adipose Tissue and Metabolism | Lifetime | 157 | FI 2 | 99.53 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 113 | FI 6 | 99.48 |
| Pancreatic function and diabetes | Lifetime | 218 | FI 4 | 99.20 |
| Lipid metabolism and disorders | Lifetime | 54 | FI 3 | 99.06 |
| Muscle metabolism and nutrition | Lifetime | 146 | FI 1 | 99.07 |
| Cardiovascular Health and Disease Prevention | Lifetime | 219 | FI 7 | 98.80 |
| Diabetes and associated disorders | Lifetime | 294 | FI 15 | 98.61 |
| Lipid metabolism and biosynthesis | Lifetime | 134 | FI 2 | 98.28 |
| Pharmacology and Obesity Treatment | Lifetime | 154 | FI 6 | 98.08 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 628 | FI 14 | 97.44 |
| Alcohol Consumption and Health Effects | Lifetime | 408 | FI 6 | 97.11 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 528 | FI 8 | 96.63 |
| Blood Pressure and Hypertension Studies | Lifetime | 998 | FI 20 | 97.41 |
| Cardiovascular and exercise physiology | Lifetime | 906 | FI 24 | 96.68 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 468 | FI 8 | 94.73 |
| HIV-related health complications and treatments | Lifetime | 850 | FI 2 | 94.31 |
| Occupational Health and Performance | Lifetime | 972 | FI 38 | 87.32 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 76 | FI 1 | 99.55 |
| Diet, Metabolism, and Disease | 2021-2025 | 31 | FI 1 | 99.27 |
| Diet and metabolism studies | 2021-2025 | 242 | FI 2 | 97.19 |
| Alcohol Consumption and Health Effects | 2021-2025 | 498 | FI 5 | 84.63 |
| Lipid metabolism and disorders | 2021-2025 | 946 | FI 6 | 59.41 |